Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(50%)

Phase Distribution

Ph phase_3
1
50%
Ph early_phase_1
1
50%

Phase Distribution

1

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Early Phase 1First-in-human
1(50.0%)
Phase 3Large-scale testing
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Terminated(1)

Detailed Status

Enrolling by invitation1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (50.0%)
Phase 31 (50.0%)

Trials by Status

enrolling_by_invitation150%
terminated150%

Recent Activity

0 active trials
Showing 2 of 2
enrolling_by_invitationearly_phase_1

Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.

NCT07358234
terminatedphase_3

Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)

NCT03245840

Clinical Trials (2)

Showing 2 of 2 trials
NCT07358234Early Phase 1

Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.

Enrolling By Invitation
NCT03245840Phase 3

Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)

Terminated

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2